Bioviva’s aims to be an advanced medicinal product access platform. To this end bioviva is committed to the following:
May 17 , 2018

Bioviva’s aims to be an advanced medicinal product access platform. To this end bioviva is committed to the following:

  • Bridging stakeholders with biotechnology
  • Accelerated path to human trials
  • Growing knowledge base
  • Ensuring dependability


BioViva is a platform to expedite the development of drugs and treatments that affect human healthspan. To achieve this goal BioViva has developed a comprehensive set of biomarkers of aging, which include molecular, physiological, anatomical, clinical, and qualitative markers. BioViva also collaborates with clinicians, biomedical scientists, and statisticians to develop innovative protocols for adaptive clinical trials for gene and cell therapies. Finally, BioViva has built a bioinformatics pipeline to analyze the data generated from the biomarkers of aging in human trials and validate the treatments that are effective for treating the aging process.

BioViva has recently partnered with a patient-paid-for clinical trial company Integrated Health Systems (IHS). IHS connects doctors with patients who want to take part in paid-for clinical trials. During our collaboration with IHS, they will utilize our adaptive clinical trial protocols to conduct gene and cell therapy trials. All patients will undergo pre- and post-testing using BioViva’s comprehensive biomarkers of aging platform. Treatment efficacy and patient well being will be assessed using our bioinformatics pipeline.

The goal of BioViva is to accelerate the development of products that will effectively, and cost-efficiently treat biological aging. Our platform is designed to provide expedited and reliable feedback to our clinical and manufacturing partners, so that they may rapidly iterate their products and services to help patients improve the quality and quantity of life.

Success for BioViva entails finding therapies that work quantitatively by reversing or slowing biological aging in humans as measured by DNA methylation, metabolic, physiological, anatomical, and clinical markers. In addition, we will qualitatively improve patient well-being by helping them achieve an optimally healthy life.

BioViva is a platform for anti-aging biotech development. BioViva is to biotech, what meta-analysis is to medical research. BioViva’s platform is designed to accommodate all forms of research and development that target the aging process in humans. We work with biotech companies and biologic manufacturers and help them conduct accelerated adaptive clinical trials to ascertain the efficacy of their products in treating the aging process.

According to FDA drug approvals between 2004 and 2014, there is a 15 percent chance of going from Phase 1 through to FDA approvals for biologics, and a 7 percent chance of success for small molecules. This high rate of failure highlights the problems with preliminary drug testing platform. BioViva is a cost-effective solution for biotech companies to rapidly test their drugs in humans to determine where to embark on the expensive and time-consuming FDA or EMA approval process.

The biggest challenge in evaluating the efficacy of anti-aging treatments are biomarkers of aging. Currently, our the best biomarkers of aging are loosely associated with biological aging especially in people aged over 50.

This is clearly the biggest problem as we cannot wait for 10 years to test every treatment. Therefore at BioViva, we have designed a comprehensive biomarker of aging platform that should be able to ascertain anti-aging treatment efficacy within a couple of years.

In summary, we want to help humans live long and healthy lives, and we have built a platform to assess anyone’s products that can help us achieve that goal.

Adam Alonzi

Adam Alonzi is a writer, biotechnologist, documentary maker, futurist, inventor, programmer, and author two novels. He is an analyst for the Millennium Project, and Head of Social Media and Content Creation for BioViva Sciences. Listen to his podcasts here. Read his blog here.